Review article Imiquimod applied topically: A novel immune response modifier and new class of drug

International Journal of Immunopharmacology

Volumn 21, Issue 1, 1999, Pages 1-14

  Miller, R L ^a   Gerster, J F ^a   Owens, M L ^a   Slade, H B ^a   Tomai, M A ^a  

^a 3M COMPANY   (United States)

Author keywords

Cell mediated immunity; Condylomata acuminata; Cytokines; Human papillomavirus; Imiquimod; Immune response modifier; Interferon; Mechanism of action; Monocytes; Preclinical; Review; Therapy

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; AMINOQUINOLINE DERIVATIVE; ANTIVIRUS AGENT; IMMUNOLOGICAL ADJUVANT;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION; VIRUS INFECTION; WART VIRUS; ANIMAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANIMALS; ANTIVIRAL AGENTS; HUMANS;

EID: 0032619393     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(98)00068-X     Document Type: Review

References (58)

1. Arany, I., & Tyring, S. K. (1996). Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J. Interferon Cytokine Res., 16, 453-460.
2. Bernstein, D. I., & Harrison, C. J. (1989). Effects of the immunomodulating agent R-837 on acute and latent herpes simplex virus type 2 infections. Antimicro. Agents and Chemotherapy, 33, 1511-1515.
3. Bernstein, D. I., Miller, R. L., & Harrison, C. J. (1993a). Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development. Antiviral Res., 20, 45-55.
4. Bernstein, D. I., Miller, R. L., & Harrison, C. J. (1993b). Adjuvant effects on imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J. Infect. Dis., 167, 731-735.
5. Bernstein, D. I., Harrison, C. J., Tepe, E. R., Shahwan, A., & Miller, R. L. (1995). Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs. Vaccine, 13, 72-76.
6. Beutner, K., Edwards, L., Tyring, S., Ferenczy, A., Owens, M., Fox, T., Hougham, A., Gayoso, K., & Study Group. (1996). Comparison of results from two vehicle controlled clinical trials of topical imiquimod for the treatment of genital/perianal warts. (Abstract ) Presented at American Academy of Dermatology 54th Annual Meeting, Washington DC.
7. Beutner, K. R., & Geisse, J. K. (1997). Imiquimod-an immune response modifier for the treatment of genital warts. Todays Therapeutic Trends, 15, 165-178.
8. Beutner, K. R., Spruance, S. L., Hougham, A. J., Fox, T. L., Owens, M. L., & Douglas, J. M. (1998). Treatment of genital warts with an immune-response modifier (imiquimod). J. Amer. Acad. Derm., 38, 230-239.
9. Beutner, K. R., Tyring, S. K., Trofatter, K. F., Douglas, J. M., Spruance, S., Owens, M. L., Fox, T. L., Hougham, A. J., & Schmitt, K. A. (1998a). Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrobial Agents Chemother., 42, 789-794.
10. Bonnez, W., DaRin, C., Borkhuis, C., Rose, R. C., & Miller, R. (1996). Evaluation of imiquimod (Aldara™) in the human papillomavirus (HPV) type II-infected infected external human-severe combined immunodeficiency (SCID) mouse model. (Abstract ) Presented at 15th International Papillomavirus Workshop, Queensland, Australia.
11. Borden, E. C., Sidky, Y. A., & Weeks, C. E. (1991). Mechanisms of anti-tumor action of the interferon inducer R-837. (Abstract) Proc. Amer. Assoc. for Cancer Res., 32, 258.
12. Bottrel, R. A. T., Levy, D. E., Tomai, M., & Reis, L. F. L. (1997). STAT-1 is a key target for imiquimod, an oral inducer of interferon. (Abstract) J. Interferon and Cytokine Research, 17(Suppl 2), S62.
13. Buates, S., & Matlashewski, G. (1997a). Suppression of macrophage infection with L. donovani using the macrophage activation compound, imiquimod. (Abstract) Presented at World Congress on Leishmania, Istanbul, Turkey.
14. Buates, S., & Matlashewski, G. (1997b). Induction of the Leishmanicidal activity in macrophage by the immunomodulator imidazoquinoline. (Abstract ) Presented at Molecular Parasitology Meeting, Woods Hole, Mass.
15. Chen, M., Griffith, B. P., Lucia, H. L., & Hsiung, G. D. (1988). Efficacy of S-26308 against guinea pig cytomegalovirus infection. Antimicro. Agents and Chemo., 32, 678-683.
16. Coleman, N., Birley, H. D. L., Renton, A. M., Hanna, N. F., Ryait, B. K, Byrne, M., Taylor-Robinson, D., & Stanley, M. A. (1994). Immunological events in regressing genital warts. Am. J. Clin. Pathol., 102, 768-774.
17. Conant, M. A., Opp, K. M., Gilson, R. J. C., Shupack, J. L., Friedman-Kien, A. E., Owens, M. L., Smith, M. H., Pietig, D. C., Kapsner, C. K., Tygum, K. I., & HPV Study Group. (1998). A vehicle-controlled safety and efficacy trial evaluating 5% imiquimod cream for the treatment of genital/perianal warts in HIV-positive patients. (Abstract) Presented at American Academy of Dermatology 56th Annual Meeting, Orlando, FL.
18. Couch, R. B., Kasel, J. A., Glezen, W. P., Cate, T. R., Six, H. R., Taber, L. H., Frank, A. L., Greenberg, S. B., Zahradhik, J. M., & Keitel, W. A. (1986). Inflenza: its control in persons and populations. J. Infect. Dis., 153, 431-440.
19. De Benedetti, A., Pytel, B. A., & Baglioni, C. (1987). Loss of (2′-5′)oligoadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections. Proc. Natl. Acad. Sci. U.S.A., 84, 658-662.
20. Edwards, L., Ferenczy, A., Eron, L., Baker, D., Owens, M. L., Fox, T. L., Hougham, A. J., Schmitt, K. A., & HPV Study Group. (1998). Self administered topical 5% imiquimod cream for external anogenital warts. Arch. Derm., 134, 25-30.
21. Frank, G. (1983). Bacteria as etiologic agents in bovine respiratory disease. In R. W. Loan (Ed.), Bovine Respiratory Disease, A Symposium, (pp. 247-262).
22. Gibson, S. J., Imbertson, L. M., Wagner, T. L., Testerman, T. L., Reiter, M. J., Miller, R. L., & Tomai, M. A. (1995). Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Interferon and Cytokine Res., 15, 537-545.
23. Goldstein, D., Hertzog, P., Tomkinson, E., Couldwell, D., McCarville, S., Parrish, S., Cunningham, P., Newell, M., Owens, M. & Cooper, D. A. (1998). Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J. Infect. Dis., 178, 858-861.
24. Hammerbeck, D. M., Tomai, M. A., Hupperts, A. M., McGurran, S. M., Reiter, M. J., & Wagner, T. L. (1997). The imidazoquinolines and related compounds as inhibitors of pulmonary eosinophilia. (Abstract) Amer. J. Resp. Crit. Care Med., 155, A624.
25. Harrison, C. J., Jenski, L., Voychehovski, T., & Bernstein, D. I. (1988). Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res., 10, 209-224.
26. Harrison, C. J., Stanberry, L. R., & Bernstein, D. I. (1991). Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs. Antiviral Res., 15, 315-322.
27. Harrison, C. J., Miller, R. L., & Bernstein, D. I. (1994) Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV- specific T-cell memory by imiquimod in guinea pigs. Antimicro. Agents and Chemo., 38, 2059-2064.
28. Imbertson, L., Weeks, C., Adams, N., McCarville, S., Finley, D., Holtzman, J., Miller R., & Kvam, D. (1992). Induction of antiviral activity and cytokines by oral imiquimod in healthy volunteers. (Abstract) J. Interferon Res., 12(Supp1. 1), S127.
29. Imbertson, L. M., Beurline, J. M., Couture, A. M., Gibson, S. J., Smith, R. M. A., Miller, R. L., Reiter, M. J., Wagner, T. L., & Tomai, M. A. (1998). Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol., 110, 734-739.
30. Kende, M., Lupton, H. W., & Canonico, P. G. (1988). Treatment of experimental viral infections with immu-nomodulators. Adv. Biosci., 68, 51-63.
31. Kono, T., Kondo, S., Pastore, S., Shivji, G. M., Tomai, M. A., McKenzie, R. C., & Sauder, D. N. (1994). Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine and Cytokine Research, 13, 71-76.
32. Koutsky, L. (1997). Epidemiology of genital human papillomavirus infections. Am. J. Med., 102, 3-8.
33. MacKenzie-Wood, A., de Launey, J., Kossard, S., Svans, R., Fox, T., & Owens, M. (1998). Safety and efficacy of imiquimod 5% cream for the treatment of Bowen's Disease. (Abstract) J. Invest. Derm., 110, 684.
34. Megyeri, K., Au, W.-C., Rosztoczy, I., Raj, N. B. K., Miller, R. L., Tomai, M. A., & Pitha, P. M. (1995). Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by sendai virus utilize similar signal transduction pathways. Molecular and Cellular Biology, 15, 2207-2218.
35. Miller, R. L., Imbertson, L. M., Reiter, M. J., Schwartzmiller, D. H., Pecore, S. E., & Gerster, J. F. (1985). Inhibition of herpes simplex virus infections in a guinea pig model by S-26308. (Abstract) Presented at the Twenty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN.
36. Miller, R. L., Imbertson, L. M., Reiter, M. J., Pecore, S. E., & Gerster, J. F. (1986). Interferon induction by antiviral S-26308 in guinea pigs. (Abstract) Presented at the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA.
37. Miller, R., Birmachu, W., Gerster, F., Gibson, S., Imbertson, L., Reiter, M., Scribner, L., Tomai, M., Weeks, C., & Wagner, T. (1994). Cytokine-induction by imiquimod, preclinical results and pharmacology. Chemotherapie J., 4, 148-150.
38. Miller, R., Birmachu, W., Gerster, J., Gibson, S., Imbertson, L., Reiter, M., Scribner, L., Wagner, T., Weeks, C., & Tomai, M. (1995). Imiquimod: cytokine induction and antiviral activity. Intl. Antiviral News, 3, 111-113.
39. Owens, M. L., Tygum, K. I., Senta, T. A., Myers, J. A., Fox, T. L., & Smith, M. H. (1997). A safety assessment of topical imiquimod. (Abstract) Presented at 19th World Congress of Dermatology, Sydney, Australia.
40. Reiter, M. J., Testerman, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994). Cytokine induction in mice by the immunomodulator imiquimod. J. Leukocyte Biol., 55, 234-240.
41. Rogge, L., Barberis-Maino, L., Biffi, M., Passini, N., Presky, D. H., Gubler, U., & Sinigaglia, F. (1997). Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med., 185, 825-831.
42. Savage, P., Horton, V., Moore, J., Owens, M., Witt, P., Gore, M. E. (1996). A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. British J. Cancer, 74, 1482-1486.
43. Shiratsuchi, H., Sherman, J., Miller, R. L., & Ellner, J. J. (1995). Cytokine induction and anti-Mycobacterium avium activity of human monocytes stimulated with imidazoquinolinamines. (Abstract) 35th Intersci. Conf. Antimic. Agents Chemother., G110, 177.
44. Sidky, Y. A., Borden, E. C., Weeks, C. E., Reiter, M. J., Hatcher, J. F., & Bryan, G. T. (1992). Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res., 52, 3528-3533.
45. Slade, H. B., Owens, M. L., Tomai, M. A., & Miller, R. L. (1998). Imiquimod 5% cream (Aldara™). Exp. Opin. Invest. Drugs, 7, 437-449.
46. Stokes, J. R., Sorkness, R. L., Kaplan, M. R., Castleman, W. L., Tomai, M. A. Miller, R. L., & Lemanske RF. (1998). Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. European Respiratory J., 11, 324-329.
47. Suzuki, H., Wang, B., Amerio, P., Toto, P., Shivji, G., Miller, R., McDermott, D., Tomai, M., & Sauder, D. N. (1998). Imiquimod, a novel topical immune response modifier induces migration of Langerhans cells. (Abstract) J. Invest. Derm., 110, 566.
48. Szabo, S. J., Dighe, A. S., Gubler, U., & Murphy, K. M. (1997). Regulation of the interleukin (IL)- 12R B2 subunit expression in developing T helper 1 (Th1) and (Th2) Cells. J. Exp. Med., 185, 817-824.
49. Tagami, H., Oku, T., & Iwatsuki, K. (1985). Primary tissue culture of spontaneously regressing flat warts. Cancer, 55, 437-2441.
50. Testerman, T. L., Gerster, J. F., Imbertson, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J., Wagner, T. L., & Tomai, M. (1995). Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leuk. Biol., 58, 365-372.
51. Tomai, M., Imbertson, L., Wagner, T., Reiter, M., & Miller, R. (1994) Activation of human and mouse B lymphocytes by the immunomodulators imiquimod and S-27609. (Abstract) FASEB J., Part I, 4, A253.
52. Tomai, M. A., Birmachu, W., Case, M. T., Gerster, J. F., Gibson, S. J., Imbertson, L. M., Miller, R. L., Reiter, M. J., & Wagner, T. L. (1997). Imiquimod: in vivo and in vitro characteristics and toxicology. In R. Aly, K. R. Beutner & H. Maibach (Eds.), Cutaneous Infection and Therapy Vol. 32 (pp. 405-415).
53. Tomai, M. A., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Vasilakos, J. P., & Wagner, T. L. (1998). Effects of the imidazoquinolines, imiquimod and S-28463, on Th1 and Th2 cytokine responses in vitro. (Abstract) J. Invest. Derm., 110, 651.
54. Tygrett, L. T., Li, X., Tomai, M., & Waldschmidt, T. J. (1995). Imidazoquinolinamines, a new class of immunomodulating drugs, are direct B cell mitogens. (Abstract) Presented at Midwest Immunology Conference, Chicago, IL.
55. Tyring, S. K., Arany, I., Stanley, M. A., Tomai, M. A., Miller, R. L., Smith, M. H., McDermott, D. J., & Slade, H. B. (1998). A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis., 178, 551-555.
56. Wagner, T. L., Horton, V. L., Carlson, G. L., Myhre, P. P., Gibson, S. J., Imbertson, L. M., & Tomai, M. A. (1997). Induction of cytokines in Cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine., 9, 837-845.
57. Weeks, C. E., & Gibson, S. J. (1994). Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J. Interferon Res., 14, 81-85.
58. Witt, P. L., Ritch, P. S., Reding, D., McAuliffe, T. L., Westrick, L., Grossberg, S. E., & Borden, E. C. (1993) Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res., 53, 5176-5180.